IL-UNITAS-GLOBAL
9.5.2022 13:32:09 CEST | Business Wire | Press release
Unitas Global, a Digital Alpha portfolio company, announces today that it has acquired INAP’s Network Business assets, including INAP Japan, enhancing its portfolio of network service offerings that enable hybrid cloud environments. The combination of these two companies creates a high-growth next generation networking platform focused on simplifying the way customers buy network connectivity to enable the seamless movement of data between various cloud and on-premises environments.
The combination of the INAP network technologies, including its patented, intelligent routing software, Managed Internet Route Optimizer (MIRO), with Unitas Global's automated design and pricing platform, Unitas Nexus™ , and its global network, Unitas Reach™ , creates a compelling offer to meet the needs of enterprises modernizing their digital infrastructure. In addition, this acquisition provides Unitas Global with a significant expansion of over a thousand multinational enterprise customers as well as global network serving 18 markets with Performance IP™.
"We are thrilled to have completed the acquisition of INAP's Network Business and excited to welcome their customers, vendors and employees to the Unitas Global team," comments Patrick Shutt, CEO of Unitas Global. "The disruptive nature of Unitas' networking services strategy that enables hybrid cloud environments has become increasingly self-evident in the market. This acquisition is the next step to become the market leader redefining an agile hybrid cloud for the enterprise," comments Grant Kirkwood, CTO of Unitas Global.
An additional benefit of the transaction is the synergy of INAP becoming a strategic customer of Unitas Global. INAP will continue to offer high-performance connectivity services alongside its colocation and cloud solutions, further expanding its portfolio with Unitas Reach™ network transformation solutions, including the most recent alliance announcement with PacketFabric.
“The transaction is a true win-win for everyone involved. Unitas Global will continue to provide the high-quality services that customers enjoy today while investing in new solutions to enable further network transformation tomorrow," comments Mike Sicoli, CEO of INAP. "We also look forward to partnering with Unitas Global to bring an expanded portfolio of connectivity offerings to our colocation and cloud customers."
"The acquisition of INAP’s Network Business assets is a powerful proof point of Digital Alpha's commitment to investing in and developing transformative next generation networks that provide a more holistic networking-as-a-service solution in the currently fragmented marketplace," states Rick Shrotri Managing Partner of Digital Alpha Advisors.
For more information, visit: https://www.unitasglobal.com/
About Unitas Global
Unitas Global is a next-generation network service provider offering automated ubiquitous edge access to cloud everywhere. The combination of its Unitas Nexus™ platform and global Unitas Reach™ network provides the most transformative network environments that are easy to design, procure, and fully managed. Analyzing price and performance requirements in real-time makes Unitas Nexus™ one of the most advanced go-to-market platforms for MSPs, hyperscale cloud providers, and datacenter operators worldwide. Unitas Reach™ access, IP, and SDN provide cost-optimized network connectivity with the agility needed to scale quickly and support the growing demands of applications on network architectures, performance, and costs. Unitas Global is a Digital Alpha Advisors portfolio company. Learn more at unitasglobal.com or connect with Unitas at LinkedIn , Twitter , and its Blog .
About INAP
INAP is a global provider of performance-driven, secure hybrid infrastructure solutions, enabling technology leaders to simplify their cloud journeys and accelerate innovation. INAP's expansive suite of bare metal cloud, modern data center, optimized network and security solutions help businesses flexibly and reliably move workloads to the right destination at the right time to maximize the results of their IT strategy. For more information, visit www.inap.com
About Digital Alpha Advisors, LLC
Digital Alpha Advisors, LLC is an investment firm focused on digital infrastructure required by the rapidly expanding digital economy, with total assets under management of over $1.5B. The firm has a strategic collaboration agreement with Cisco Systems, Inc. and has partnered with other leading Silicon Valley firms. Digital Alpha believes it is the first firm focused on making private equity investments in the significant growth opportunities required to underpin the Digital Economy, including next generation communications networks, IoT platforms for urban infrastructure, and cloud-based data management platforms. Digital Alpha was founded in 2017 by Rick Shrotri, former Head of the Global Infrastructure Funds (GIF) team at Cisco, and closed its latest Fund – Digital Alpha Fund II, LP – in early 2021. For more information, please visit www.digitalalpha.net .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220508005058/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom